Bo‐Eric Persson

2.3k citations

47 papers · 1.8k indexed · 1 hit paper · h-index 18

Impact in

Endocrinology, Diabetes and Metabolism top 1%
- Hormonal and reproductive studies
Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in ⓘ

Pulmonary and Respiratory Medicine 33
- Prostate Cancer Treatment and Research 32
- Prostate Cancer Diagnosis and Treatment 14
Endocrinology, Diabetes and Metabolism 16
- Hormonal and reproductive studies 16

Co-authors: Tine Kold Olesen (16 shared papers)L Boccon-Gibod (8 shared papers)Neal D. Shore (11 shared papers)Fritz H. Schröder (5 shared papers)Laurence Klotz (8 shared papers)Gunnar Ronquist (5 shared papers)Bertrand Tombal (11 shared papers)Jens-Kristian Jensen (6 shared papers)
Journals: The Journal of Urology (14 papers)Journal of Clinical Oncology (5 papers)European Urology (4 papers)Therapeutic Advances in Urology (2 papers)Pflügers Archiv - European Journal of Physiology (2 papers)
Partner nations: United States Denmark Sweden

In The Last Decade

Bo‐Eric Persson

47 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer 2008 · 447 citations

Peers

Countries citing papers authored by Bo‐Eric Persson

Since Specialization

Citations

This map shows the geographic impact of Bo‐Eric Persson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo‐Eric Persson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo‐Eric Persson more than expected).

Fields of papers citing papers by Bo‐Eric Persson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo‐Eric Persson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo‐Eric Persson. The network helps show where Bo‐Eric Persson may publish in the future.

Co-authors

The 25 scholars most cited alongside Bo‐Eric Persson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bo‐Eric Persson Line = papers co-authored together Bo‐Eric Persson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer British Journal of Urology ·Laurence Klotz, L Boccon-Gibod, Neal D. Shore, Cal Andreou, Bo‐Eric Persson, P. Cantor, Jens‐Kristian Jensen, Tine Kold Olesen, Fritz H. Schröder Hit paper breakdown →	2008	447
2	Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program The Journal of Urology ·William A. See, Manfred P. Wirth, David G. McLeod, Peter Iversen, Ira Klimberg, Donald M. Gleason, Gerald W. Chodak, James E. Montie, C. Tyrrell, D. M. A. WALLACE, K.P.J. Delaere, Sigmund Vaage, Teuvo L.J. Tammela, O Lukkarinen, Bo‐Eric Persson, Kevin Carroll, Geert J.C.M. Kolvenbag	2002	175
3	A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer The Journal of Urology ·E. David Crawford, Bertrand Tombal, Kurt Miller, L Boccon-Gibod, Fritz H. Schröder, Neal D. Shore, Judd W. Moul, Jens-Kristian Jensen, Tine Kold Olesen, Bo‐Eric Persson	2011	118
4	Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics European Urology ·Bertrand Tombal, Kurt Miller, L Boccon-Gibod, Fritz H. Schröder, Neal D. Shore, E. David Crawford, Judd W. Moul, Jens-Kristian Jensen, Tine Kold Olesen, Bo‐Eric Persson	2009	116
5	Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer European Urology ·Hendrik Van Poppel, Bertrand Tombal, Jean J. de la Rosette, Bo‐Eric Persson, Jens-Kristian Jensen, Tine Kold Olesen	2008	96
6	Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists European Urology ·Laurence Klotz, Kurt Miller, E. David Crawford, Neal D. Shore, Bertrand Tombal, Cathrina Karup, Anders Malmberg, Bo‐Eric Persson	2014	85
7	A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America The Journal of Urology ·Marc Gittelman, Peter Pommerville, Bo‐Eric Persson, Jens-Kristian Jensen, Tine Kold Olesen, (unknown)	2008	81
8	Evidence for a Mechanistic Association Between Nonbacterial Prostatitis and Levels of Urate and Creatinine in Expressed Prostatic Secretion The Journal of Urology ·Bo‐Eric Persson, Gunnar Ronquist	1996	73
9	Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer The Journal of Urology ·Matthew R. Smith, Laurence Klotz, Bo‐Eric Persson, Tine Kold Olesen, Arthur A.M. Wilde	2010	65
10	Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study British Journal of Urology ·Fritz H. Schröder, Bertrand Tombal, Kurt Miller, L Boccon-Gibod, Neal D. Shore, E. David Crawford, Judd W. Moul, Tine Kold Olesen, Bo‐Eric Persson	2009	58
11	Ameliorative Effect of Allopurinol on Nonbacterial Prostatitis: A Parallel Double-Blind Controlled Study The Journal of Urology ·Bo‐Eric Persson, Gunnar Ronquist, Marianne Ekblom	1996	50
12	Will GnRH antagonists improve prostate cancer treatment? Trends in Endocrinology and Metabolism ·Ilpo Huhtaniemi, Richard White, Craig A. McArdle, Bo‐Eric Persson	2008	48
13	Degarelix versus Goserelin (+ Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233) Urologia Internationalis ·John Anderson, Ghandi Al-Ali, Manfred Wirth, Joan Benejam Gual, Francisco Gómez Veiga, Enrico Colli, Egbert van der Meulen, Bo‐Eric Persson	2012	46
14	An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer SHILAP Revista de lepidopterología ·L Boccon-Gibod, Egbert van der Meulen, Bo‐Eric Persson	2011	45
15	Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix Urology ·E. David Crawford, Neal D. Shore, Judd W. Moul, Bertrand Tombal, Fritz H. Schröder, Kurt Miller, L Boccon-Gibod, Anders Malmberg, Tine Kold Olesen, Bo‐Eric Persson, Laurence Klotz	2014	43
16	Monoclonal antibodies against human prostasomes The Prostate ·B. Ove Nilsson, Meishan Jin, Barbro Einarsson, Bo‐Eric Persson, Gunnar Ronquist	1998	34
17	The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients Urology ·Jan‐Erik Damber, Teuvo L.J. Tammela, Peter Iversen, Per‐Anders Abrahamsson, L Boccon-Gibod, Tine Kold Olesen, Egbert van der Meulen, Bo‐Eric Persson	2012	22
18	Degarelix: A New Approach for the Treatment of Prostate Cancer Neuroendocrinology ·Bo‐Eric Persson, Tine Kold Olesen, Jens-Kristian Jensen	2009	20
19	Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials Therapeutic Advances in Urology ·Peter Iversen, Jan‐Erik Damber, Anders Malmberg, Bo‐Eric Persson, Laurence Klotz	2015	13
20	The existence of a tubulo-glomerular feedback mechanism in the Amphiuma nephron Pflügers Archiv - European Journal of Physiology ·Bo‐Eric Persson, A. Erik G. Persson	1981	10

About Bo‐Eric Persson

Bo‐Eric Persson is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism, Urology, Nephrology and Cancer Research, having authored 47 papers that have together received 1.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (32 papers), Hormonal and reproductive studies (16 papers), Prostate Cancer Diagnosis and Treatment (14 papers), Cancer, Lipids, and Metabolism (6 papers), Urinary Bladder and Prostate Research (5 papers), Sexual Differentiation and Disorders (4 papers), Ion Transport and Channel Regulation (4 papers) and PARP inhibition in cancer therapy (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (856 citations), Pulmonary and Respiratory Medicine (1.4k citations), Urology (137 citations), Cancer Research (262 citations) and Reproductive Medicine (96 citations). Bo‐Eric Persson has collaborated with scholars based in United States, Denmark and Sweden. Frequent co-authors include Tine Kold Olesen, L Boccon-Gibod, Neal D. Shore, Fritz H. Schröder, Laurence Klotz, Gunnar Ronquist, Bertrand Tombal, Jens-Kristian Jensen, P. Cantor and Kurt Miller. Their work appears in journals such as The Journal of Urology, Journal of Clinical Oncology, European Urology, Therapeutic Advances in Urology and Pflügers Archiv - European Journal of Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact